

**Senate Community Affairs Committee**

**ANSWERS TO ESTIMATES QUESTIONS ON NOTICE**

**HEALTH AND AGEING PORTFOLIO**

**Additional Estimates 13 & 15 February 2013**

**Question: E13-058**

**OUTCOME 2: Access to Pharmaceutical Services**

**Topic:** Chemotherapy Drugs

**Type of Question:** Written Question on Notice

**Senator:** Senator Boyce

**Question:**

Because pharmacies have lost this funding source, what analysis has the department undertaken as to what impact this will have on the future of reinvestment strategies of public pharmacists?

**Answer:**

The Department of Health and Ageing has sought evidence of the expected impact of price disclosure changes on both public and private pharmacies and hospitals. To date, there has been no indication from public hospitals or pharmacists that their reinvestment strategies will change as a result of the price disclosure of Docetaxel.